CytomX Therapeutics, Inc. (CTMX) Financials

CTMX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 205.2 million 252.6 million
2023-09-30 221.2 million 272.4 million
2023-06-30 209.2 million 294.2 million
2023-03-31 234.6 million 321.3 million

CTMX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 -22.2 million 2.6 million
2023-09-30 -18.3 million 1.2 million
2023-06-30 -25.7 million 2.4 million
2023-03-31 9.3 million 2.4 million

CTMX Net Income

No data available :(

CTMX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 174.5 million - 14.0 million
2023-09-30 194.1 million - 15.1 million
2023-06-30 180.9 million - 16.1 million
2023-03-31 204.5 million - 17.1 million

CTMX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 67.3 million
2023-09-30 81.0 million
2023-06-30 66.5 million
2023-03-31 66.2 million

CTMX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 266000 18.9 million 7.8 million 37000
2023-09-30 9000 16.4 million 6.8 million -
2023-06-30 517000 20.7 million 7.4 million -
2023-03-31 48000 21.2 million 8.0 million -

CTMX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 26.6 million 486000
2023-09-30 26.4 million 1.4 million
2023-06-30 24.7 million 1.5 million
2023-03-31 23.5 million 1.5 million

CTMX

Price: $5.13

52 week price:
1.04
5.13

Earnings Per Share: -0.01 USD

P/E Ratio: -10.20

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 865300

Ebitda: -10.5 million

Market Capitalization: 142.9 million

Links: